Posted by Michael Wonder on 05 Mar 2024
Ellipses' next generation selective RET inhibitor EP0031/A400 granted fast track designation by US FDA
5 March 2024 - Ellipses Pharma announced today that it has received fast track designation from the US FDA for its next generation selective RET inhibitor EP0031/A400 for the potential treatment of RET fusion positive non-small-cell lung cancer.
This announcement follows the FDA's decision in November 2023 to grant orphan drug designation to EP0031/A400.
